Zelia Gouveia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zelia Gouveia has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Franck Perez
Institut Curie, PSL Research University, Paris, France
21 shared publications - Ariane Biquand
Mnemo Therapeutics, Paris, France
17 shared publications - Armelle Bohineust
Mnemo Therapeutics, Paris, France
17 shared publications - Christel Goudot
Institut Curie, PSL Research University, INSERM, U932, Paris, France
17 shared publications - Irena Chacón
Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris, France
17 shared publications - Jaime R. Fuentealba
Institut Curie
17 shared publications
Latest Publications
- Open Access
- 1 November 2024
- Published by EDP Sciences in médecine/sciences
- Vol. 40 (11) , 848-857
Les nouvelles générations de cellules CAR-T
L’approche CAR-T, qui consiste à utiliser des lymphocytes T exprimant un récepteur de l’antigène recombinant (CAR, pour chimeric antigen receptor) permettant d’éliminer les cellules présentant un antigène particulier, est l’une des immunothérapies les plus prometteuses pour soigner les cancers. L’ingénierie des CAR-T a évolué au fil de leurs générations, pour renforcer leur activité et leur spécificité, et surmonter leurs limites, comme leur faible persistance, leur toxicité et leur inefficacité dans la lutte contre les tumeurs solides. Cette revue explore les différentes générations de CAR, les tests cliniques en cours sur le cancer et les maladies auto-immunes, ainsi que les limites associées aux cellules CAR-T dans le traitement des cancers.
- 1 November 2024
- Published by EDP Sciences in médecine/sciences
- Vol. 40 (11) , 848-857
Open AccessLes nouvelles générations de cellules CAR-T
L’approche CAR-T, qui consiste à utiliser des lymphocytes T exprimant un récepteur de l’antigène recombinant (CAR, pour chimeric antigen receptor) permettant d’éliminer les cellules présentant un antigène particulier, est l’une des immunothérapies les plus prometteuses pour soigner les cancers. L’ingénierie des CAR-T a évolué au fil de leurs générations, pour renforcer leur activité et leur spécificité, et surmonter leurs limites, comme leur faible persistance, leur toxicité et leur inefficacité dans la lutte contre les tumeurs solides. Cette revue explore les différentes générations de CAR, les tests cliniques en cours sur le cancer et les maladies auto-immunes, ainsi que les limites associées aux cellules CAR-T dans le traitement des cancers.
- 14 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (760) , eadl0715
Acyl-CoA binding protein for the experimental treatment of anorexia
Extracellular acyl-coenzyme A binding protein [ACBP encoded by diazepam binding inhibitor (DBI)] is a phylogenetically ancient appetite stimulator that is secreted in a nonconventional, autophagy-dependent fashion. Here, we show that low ACBP/DBI plasma concentrations are associated with poor prognosis in patients with anorexia nervosa, a frequent and often intractable eating disorder. In mice, anorexia induced by chronic restraint stress (CRS) is accompanied by a reduction in circulating ACBP/DBI concentrations. We engineered a chemical-genetic system for the secretion of ACBP/DBI through a biotin-activatable, autophagy-independent pathway. In transgenic mice expressing this system in hepatocytes, biotin-induced elevations in plasma ACBP/DBI concentrations prevented anorexia induced by CRS or chemotherapeutic agents including cisplatin, doxorubicin, and paclitaxel. ACBP/DBI reversed the CRS or cisplatin-induced increase in plasma lipocalin-2 concentrations and the hypothalamic activation of anorexigenic melanocortin 4 receptors, for which lipocalin-2 is an agonist. Daily intravenous injections of recombinant ACBP/DBI protein or subcutaneous implantation of osmotic pumps releasing recombinant ACBP/DBI mimicked the orexigenic effects of the chemical-genetic system. In conclusion, the supplementation of extracellular and peripheral ACBP/DBI might constitute a viable strategy for treating anorexia.
- 14 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (760) , eadl0715
Acyl-CoA binding protein for the experimental treatment of anorexia
Extracellular acyl-coenzyme A binding protein [ACBP encoded by diazepam binding inhibitor (DBI)] is a phylogenetically ancient appetite stimulator that is secreted in a nonconventional, autophagy-dependent fashion. Here, we show that low ACBP/DBI plasma concentrations are associated with poor prognosis in patients with anorexia nervosa, a frequent and often intractable eating disorder. In mice, anorexia induced by chronic restraint stress (CRS) is accompanied by a reduction in circulating ACBP/DBI concentrations. We engineered a chemical-genetic system for the secretion of ACBP/DBI through a biotin-activatable, autophagy-independent pathway. In transgenic mice expressing this system in hepatocytes, biotin-induced elevations in plasma ACBP/DBI concentrations prevented anorexia induced by CRS or chemotherapeutic agents including cisplatin, doxorubicin, and paclitaxel. ACBP/DBI reversed the CRS or cisplatin-induced increase in plasma lipocalin-2 concentrations and the hypothalamic activation of anorexigenic melanocortin 4 receptors, for which lipocalin-2 is an agonist. Daily intravenous injections of recombinant ACBP/DBI protein or subcutaneous implantation of osmotic pumps releasing recombinant ACBP/DBI mimicked the orexigenic effects of the chemical-genetic system. In conclusion, the supplementation of extracellular and peripheral ACBP/DBI might constitute a viable strategy for treating anorexia.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Numbers of cells analyzed by single-cell ATAC-seq. Related to Figures 5 and S7.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Numbers of cells analyzed by single-cell ATAC-seq. Related to Figures 5 and S7.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
List of OFF-target sites for Suv-1 gRNA. Differentially expressed genes between mock and gSUV CD8+ T cells by Nanostring. Related to Figures 1 and S1, S2.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
List of OFF-target sites for Suv-1 gRNA. Differentially expressed genes between mock and gSUV CD8+ T cells by Nanostring. Related to Figures 1 and S1, S2.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Gene signatures used in the study. Related to Figures 3, 4, 5, S4, S5, S6, and S7.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Gene signatures used in the study. Related to Figures 3, 4, 5, S4, S5, S6, and S7.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Gene signatures used in the study. Related to Figures 3, 4, 5, S4, S5, S6, and S7.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Gene signatures used in the study. Related to Figures 3, 4, 5, S4, S5, S6, and S7.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S8 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Supplementary Figures and Legends, Supplementary Table Legends Supplementary Figure S1.Engineering SUV39H1-deficient human T cells. Supplementary Figure S2. SUV39H1-deficient T cells show enhanced stem/memory and less effector/exhausted phenotype. Supplementary Figure S3. SUV39H1 deletion in CAR T cells promotes stronger rejection of liquid and solid tumors. Supplementary Figure S4. Single-cell transcriptomics reveals enrichment of stem/memory cells and signatures in SUV39H1-deficient CAR T cells. Supplementary Figure S5. Enhanced self-renewal in SUV39H1-deficient stem/memory populations. Supplementary Figure 6. SUV39H1-deficient memory CAR T cell signature correlates with clinical response. Supplementary Figure 7. SUV39H1 ablation induces chromatin opening at stem/memory loci in all CAR T cell subpopulations. Supplementary Figure 8. SUV39H1-deficient BBz-CAR T cells show stronger memory persistence and mediate long-term protection against tumor rechallenge.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S8 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Supplementary Figures and Legends, Supplementary Table Legends Supplementary Figure S1.Engineering SUV39H1-deficient human T cells. Supplementary Figure S2. SUV39H1-deficient T cells show enhanced stem/memory and less effector/exhausted phenotype. Supplementary Figure S3. SUV39H1 deletion in CAR T cells promotes stronger rejection of liquid and solid tumors. Supplementary Figure S4. Single-cell transcriptomics reveals enrichment of stem/memory cells and signatures in SUV39H1-deficient CAR T cells. Supplementary Figure S5. Enhanced self-renewal in SUV39H1-deficient stem/memory populations. Supplementary Figure 6. SUV39H1-deficient memory CAR T cell signature correlates with clinical response. Supplementary Figure 7. SUV39H1 ablation induces chromatin opening at stem/memory loci in all CAR T cell subpopulations. Supplementary Figure 8. SUV39H1-deficient BBz-CAR T cells show stronger memory persistence and mediate long-term protection against tumor rechallenge.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S8 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Supplementary Figures and Legends, Supplementary Table Legends Supplementary Figure S1.Engineering SUV39H1-deficient human T cells. Supplementary Figure S2. SUV39H1-deficient T cells show enhanced stem/memory and less effector/exhausted phenotype. Supplementary Figure S3. SUV39H1 deletion in CAR T cells promotes stronger rejection of liquid and solid tumors. Supplementary Figure S4. Single-cell transcriptomics reveals enrichment of stem/memory cells and signatures in SUV39H1-deficient CAR T cells. Supplementary Figure S5. Enhanced self-renewal in SUV39H1-deficient stem/memory populations. Supplementary Figure 6. SUV39H1-deficient memory CAR T cell signature correlates with clinical response. Supplementary Figure 7. SUV39H1 ablation induces chromatin opening at stem/memory loci in all CAR T cell subpopulations. Supplementary Figure 8. SUV39H1-deficient BBz-CAR T cells show stronger memory persistence and mediate long-term protection against tumor rechallenge.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S8 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Supplementary Figures and Legends, Supplementary Table Legends Supplementary Figure S1.Engineering SUV39H1-deficient human T cells. Supplementary Figure S2. SUV39H1-deficient T cells show enhanced stem/memory and less effector/exhausted phenotype. Supplementary Figure S3. SUV39H1 deletion in CAR T cells promotes stronger rejection of liquid and solid tumors. Supplementary Figure S4. Single-cell transcriptomics reveals enrichment of stem/memory cells and signatures in SUV39H1-deficient CAR T cells. Supplementary Figure S5. Enhanced self-renewal in SUV39H1-deficient stem/memory populations. Supplementary Figure 6. SUV39H1-deficient memory CAR T cell signature correlates with clinical response. Supplementary Figure 7. SUV39H1 ablation induces chromatin opening at stem/memory loci in all CAR T cell subpopulations. Supplementary Figure 8. SUV39H1-deficient BBz-CAR T cells show stronger memory persistence and mediate long-term protection against tumor rechallenge.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Numbers of cells analyzed by single-cell RNA-seq and identification genes used for cluster definitions. Related to Figures 3 and S4.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Numbers of cells analyzed by single-cell RNA-seq and identification genes used for cluster definitions. Related to Figures 3 and S4.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Differentially expressed genes between mock and gSUV clusters in CD8+ and CD4+ T cells. Related to Figures 3, 4, S4, S5.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
Differentially expressed genes between mock and gSUV clusters in CD8+ and CD4+ T cells. Related to Figures 3, 4, S4, S5.